– NCEs, peptides, mAbs and mRNA
– Discovery to Approval; medtech; diagnostics
– Oncology/IO, Inflammation, Cardio/Metabolic, Neuroscience, Infectious Diseases
Start-up and Follow-on Financings
– International network of contacts
– Non-dilutive partnering validation
– Hybrid model deployment
Corporate Strategy
– Selective M&A
– Trade sales and exits
– Divestment of non-core assets/IP
Commercialisation of late-stage assets
– Managing multiple party process and bids
– Information audits and due diligences
– Multiple territories/jurisdictions
Design and execution of partnering strategies
– Technology and product positioning
– Targeted companies’ insights
– Success metrics to agreed timeframes